Pitt Shield

Rapid Short-pulse Ultrasound Delivers Drugs Uniformly across the Murine Blood-Brain Barrier with Negligible Disruption.

Authors: Morse SV, Pouliopoulos AN, Chan TG, Copping MJ, Lin J, Long NJ, Choi JJ

Background Previous work has demonstrated that drugs can be delivered across the blood-brain barrier by exposing circulating microbubbles to a sequence of long ultrasound pulses. Although this sequence has successfully delivered drugs to the brain, concerns remain regarding potentially harmful effects from disrupting the brain vasculature. Purpose To determine whether a low-energy, rapid, short-pulse ultrasound sequence can efficiently and safely deliver drugs to the murine brain. Materials and Methods Twenty-eight female wild-type mice underwent focused ultrasound treatment after injections of microbubbles and a labeled model drug, while three control mice were not treated (May-November 2017). The left hippocampus of 14 mice was exposed to low-energy short pulses (1 MHz; five cycles; peak negative pressure, 0.35 MPa) of ultrasound emitted at a rapid rate (1.25 kHz) in bursts (0.5 Hz), and another 14 mice were exposed to standard long pulses (10 msec, 0.5 Hz) containing 150 times more acoustic energy. Mice were humanely killed at 0 (<i>n</i> = 5), 10 (<i>n</i> = 3), or 20 minutes (<i>n</i> = 3) after ultrasound treatment. Hematoxylin-eosin (H-E) staining was performed on three mice. The delivered drug dose and distribution were quantified with the normalized optical density and coefficient of variation. Safety was assessed by H-E staining, the amount of albumin released, and the duration of permeability change in the blood-brain barrier. Statistical analysis was performed by using the Student <i>t</i> test. Results The rapid short-pulse sequence delivered drugs uniformly throughout the parenchyma. The acoustic energy emitted from the microbubbles also predicted the delivered dose (<i>r</i> = 0.97). Disruption in the blood-brain barrier lasted less than 10 minutes and 3.4-fold less albumin was released into the brain than with long pulses. No vascular or tissue damage from rapid short-pulse exposure was observable using H-E staining. Conclusion The rapid short-pulse ultrasound sequence is a minimally disruptive and efficient drug delivery method that could improve the treatment, diagnosis, and study of neurologic diseases. © RSNA, 2019 <i>Online supplemental material is available for this article.</i> See also the editorial by Klibanov and McDannold in this issue.

Introduction

Purpose drug delivery with BBB opening
Study Objective Determine whether a low-energy, rapid short-pulse ultrasound sequence can efficiently and safely deliver drugs across the murine blood-brain barrier
Animal model / Human subject C57BL/6 mouse, female, 8-10 weeks, 19.2±0.95 g
Disease model healthy
MRI or image guidance method Yes (stereotactic)
Targeted brain region(s) Hippocampus
Target coordinates 3 mm lateral of sagittal suture, 0.5 mm anterior of lambdoid suture
Cargo name and characteristics Texas Red-labeled 3 kDa dextran (lysine-fixable)
Route of administration intravenous (tail vein)

Outcomes and Safety

Summary of Outcomes RaSP sequence (5 µs pulses, 1.25 kHz PRF, 10 ms bursts, 0.5 Hz, 0.35 MPa) delivered dextran uniformly across targeted hippocampus, with similar dose to long pulses (which deposit 150× more energy). BBB permeability returned to baseline within 10 min (vs >20 min for long pulses). Albumin extravasation 3.4-fold lower with RaSP. No observable tissue damage on H&E.
Duration of biological effect <10 minutes (BBB closure time)

Brain Region

Ultrasound Parameters

Ultrasound instrument Sonic Concepts single-element spherical-segment focused transducer, 1 MHz
FUS Frequency 1MHz
FUS Pressure 0.35 MPa (peak negative pressure)
FUS Mode pulsed
Pulse duration 5 µs
Duration of a single FUS session 250s (calculated)
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search